OMA Guidelines Bundle

Obesity Pharmacotherapy Supplements 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544296

Contents of this Issue

Navigation

Page 6 of 19

7 Weight Neutral Weight Loss • Fluoxetine (<1 yr) • Sertraline (<1 yr) • Venlafaxine • Desvenlafaxine • Bupropion • Ziprasidone • Lamotrigine • Levetiracetam • Phenytoin • Topiramate • Zonasamide • Ziprasidone • DPP4 inhibitors • a-glucosidase inhibitors • Acarbose • Miglitol • GLP1 RAs • Metformin • SGLT2 inhibitors • Pramlintide • Angiotensin- converting enzyme blockers (ACE) inhibitors • Angiotensin II receptor blockers (ARBs) • Calcium channel blockers (CCBs) • Thiazides • Carvedilol • Nebivolol • Barrier methods • Copper intrauterine devices (IUDs) • Surgical methods • Immunosuppressive agents • Loratadine • Fexofenadine

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy Supplements 2026